Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.


Pharmaceutical Technology


Using the inequality that, for two events A and B:

P(A and B) = P(A) + P(B) – P(A or B) ≥ P(A) + P(B) – 1

It follows that:

P(S 2) = P(C 21 and C 22) ≥ max {P(C 21) + P(C 22) – 1, 0}

Since criterion C 21 is similar to S 1 except for n = 30 and k = 2.0 in the former while n = 10 and k = 2.4 in the latter, the calculation of P(C 21) is carried out similarly as in P(S 1) with n = 30 and k = 2.0. Therefore:



Therefore, a lower bound on the probability of passing USP requirements is max {P(S 1), P(S 2)}.


Figure 1. 95% lower bound on passing the USP test for dose uniformity (target 5 100%).
For a given value of μ and a given value of σ, a lower bound (LBOUND) can be determined using the above calculations. Figure 1 shows a contour for the combinations of μ and σ that have an LBOUND of 95% assuming a target, T, of 100. Any combination of μ and σ at or below the contour results represents at least a 95% chance of samples passing the USP content uniformity test.

The "true" probability of passing the USP test can be found by simulation. Table I gives a comparison of the simulated probabilities and the LBOUND calculation.


Table I: Simulated (SIM) versus lower bound (LB) probabilities of passing content-uniformity test.
As can be seen in Table I, the LBOUND calculations are fairly close to the simulated results across various population means and standard deviations.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here